Core Insights - Kaisi China announced the upgrade of the "Marco Polo Program" to version 3.0 at the 8th China International Import Expo, emphasizing its commitment to enhancing medical accessibility and advocating for healthcare equity [1][9] - The company aims to deepen collaborations with various partners, including JD Health and the China Rare Disease Alliance, to expand its ecosystem and improve patient care [1][7] Group 1: Strategic Collaborations - Kaisi signed a strategic cooperation agreement with JD Health, allowing the full line of respiratory products to be available on JD Health, focusing on disease education, online consultations, and chronic disease management [3] - Kaisi and Shangyao Cloud Health announced an upgraded strategic partnership to enhance outpatient services through "Yiyao Pharmacy," providing comprehensive health management for respiratory diseases [5] - A memorandum of cooperation was signed with the China Rare Disease Alliance to improve rare disease management and establish standardized treatment systems [7] Group 2: Product Innovations and Market Expansion - Kaisi showcased its innovative respiratory product, the inhalation powder aerosol, at the expo, aiming to provide new treatment options for asthma patients in China [10] - The company introduced nine innovative rare disease drugs, including FILSUVEZ®, which is the first approved treatment for certain genetic skin disorders, highlighting its commitment to addressing unmet medical needs [10] - Kaisi's "CARE" specialty treatment area has already helped 1.38 million premature infants in China, demonstrating its impact on public health [9] Group 3: Commitment to Healthcare Equity - Kaisi emphasizes the importance of medical equity and has initiated various programs to enhance awareness and treatment options for premature infants and respiratory diseases [9][10] - The company aims to leverage the "spillover effect" of the Import Expo to accelerate the introduction of innovative products and improve accessibility for patients [11]

Core Insights - The 2025 EAACI Congress attracted over 7,600 attendees and is viewed as a turning point in the field of allergy and clinical immunology [1] - The congress emphasized the integration of scientific innovation, healthcare equity, and environmental health [1] - The event featured over 250 hours of lectures, workshops, and discussions on breakthroughs in drug allergies, T2 inflammation, pediatric asthma, and hereditary angioedema [1] Group 1 - The congress highlighted the issue of antimicrobial resistance from a "One Health" perspective and addressed the impact of climate change on insect allergies [1] - EAACI's commitment to community engagement was demonstrated through public activities, including the Clinical Village at the Glasgow Science Centre and the "Beat Allergy Walk & Run" event, which raised funds for Glasgow Children's Hospital Charity [2] - The collaborative spirit witnessed at the congress is being transformed into real-world initiatives and global partnerships [2] Group 2 - EAACI is dedicated to talent development, digital health innovation, and enhancing patient advocacy [2] - The countdown for the 2026 EAACI Congress has begun, with a rich calendar of events planned throughout the year for continued engagement in cutting-edge science [3] - EAACI is the largest professional association in Europe focused on advancing research and improving patient care in allergic diseases [4]